ISOTRETINOIN ASCENT isotretinoin 5mg capsule blister pack

Main information

  • Trade name:
  • ISOTRETINOIN ASCENT isotretinoin 5mg capsule blister pack
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ISOTRETINOIN ASCENT isotretinoin 5mg capsule blister pack
    Australia
  • Language:
  • English

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization status:
  • Registered
  • Authorization number:
  • 186334
  • Last update:
  • 22-05-2019

Public Assessment Report

Public Summary

Summary for ARTG Entry:

186334

ISOTRETINOIN ASCENT isotretinoin 5mg capsule blister pack

ARTG entry for

Medicine Registered

Sponsor

Douglas Pharmaceuticals Australia Pty Ltd

Postal Address

15 - 17 Chapel Street,Cremorme, VIC, 3121

Australia

ARTG Start Date

8/06/2012

Product category

Medicine

Status

Active

Approval area

Drug Safety Evaluation Branch

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. ISOTRETINOIN ASCENT isotretinoin 5mg capsule blister pack

Product Type

Single Medicine Product

Effective date

3/01/2014

Warnings

See Product Information and Consumer Medicine Information for this product

Standard Indications

Specific Indications

ISOTRETINOIN ASCENT is indicated for the treatment of patients with severe cystic acne and a single course of therapy has been shown to result in

complete and prolonged remission of disease in many patients. If a second course of therapy is needed, it should not be initiated until at least eight

weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. Because of significant

adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional

therapy, including systemic antibiotics.

Additional Product information

Container information

Type

Material

Life Time

Temperature

Closure

Conditions

Blister Pack

PVC/PVDC/Al

3 Years

Store below 25

degrees Celsius

Not recorded

Protect from Moisture

Protect from Light

Pack Size/Poison information

Pack Size

Poison Schedule

15 capsules

(S4) Prescription Only Medicine

60 capsules

(S4) Prescription Only Medicine

30 capsules

(S4) Prescription Only Medicine

90 capsules

(S4) Prescription Only Medicine

Components

1. Medicine Component

Dosage Form

Capsule, soft

Route of Administration

Oral

Visual Identification

Faint pinkish/cream to cream coloured oval, soft gelatin capsules,

containing a yellow/orange, viscous liquid.

Active Ingredients

Isotretinoin

5 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 29.11.2017 at 03:00:28 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information